Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2014
- Source ID
- 10.1016/j.bbmt.2014.07.021
Entities
People
- Celalettin Ustun
- Charles F. Lemaistre
- Christopher Dandoy
- César O. Freytes
- David Szwajcer
- Görgün Akpek
- Haydar A. Frangoul
- Hillard M Lazarus
- Karen K. Ballen
- Mahmoud Aljurf
- Nandita Khera
- Navneet S Majhail
- Paulette Mehta
- Ruta Brazauskas
- Steven Joffe
- Susan K. Parsons
- William A. Wood
- Zhiwei Wang
Organizations
- AABB
- Amgen
- Astellas Pharma (United States)
- Bailey Family Foundation
- BioMarin Pharmaceutical
- Biogen
- Blue Cross Blue Shield Association
- Celgene
- CellGenix (Germany)
- Children’s Leukemia Research Association
- Elevance Health, Inc.
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Oncology Nursing Society
- Osiris Therapeutics
- Otsuka (United States)
- Pfizer
- Roche (United States)
- Sigma-Tau Pharmaceuticals (United States)
- Terumo BCT (United States)
- Texas Instruments
- United States Public Health Service